United States Food and Drug Administration
Eli Lilly’s Zepbound Receives FDA Approval as First Prescription Drug for Moderate-to-Severe Obstructive Sleep Apnea in Adults with Obesity
GLP-1, Obstructive Sleep Apnea (OSA), Obesity, Zepbound, Tirzepatide, FDA Approval, Sleep Disorder Treatment
Cobenfy: A Breakthrough in Schizophrenia Treatment with a Novel Mechanism of Action
Cobenfy, schizophrenia, muscarinic receptors, xanomeline, trospium chloride, Bristol Myers Squibb, Karuna Therapeutics, FDA approval, antipsychotic drugs.
FDA Approves Zepbound for Obstructive Sleep Apnea in Adults with Obesity
Zepbound, FDA approval, obstructive sleep apnea, obesity, tirzepatide, sleep disorder treatment
FDA Imposes Import Restrictions on 11 Viatris Products from Indian Facility Due to Regulatory Violations
Viatris, FDA, Import Restrictions, India Facility, Regulatory Violations, Pharmaceutical Manufacturing
FDA Approves ALYFTREK, a Next-Generation CFTR Modulator for Cystic Fibrosis Treatment
ALYFTREK, cystic fibrosis, CFTR modulator, FDA approval, once-daily treatment, Vertex Pharmaceuticals
FDA Approves Alhemo: A Breakthrough Once-Daily Treatment for Hemophilia A and B with Inhibitors
Alhemo, FDA approval, hemophilia A, hemophilia B, inhibitors, concizumab, once-daily treatment, subcutaneous injection, prophylactic treatment
Eli Lilly’s Zepbound Wins Historic FDA Approval for Treating Obstructive Sleep Apnea in Adults with Obesity
Zepbound, tirzepatide, FDA approval, obstructive sleep apnea, obesity, weight loss, sleep disorder treatment
FDA Approves Humacyte’s Symvess: A Revolutionary Off-the-Shelf Artery Implant for Vascular Trauma Repair
FDA Approval, Humacyte, Symvess, Vascular Trauma, Off-the-Shelf Artery Implant, Bioengineered Human Tissue, Extremity Vascular Trauma Treatment
Biotech Industry’s Turbulent Year: Fierce Biotech’s Top 10 Most-Read Stories of 2024
Biotech industry, layoffs, site shutdowns, FDA rejections, M&A deals, J.P. Morgan Healthcare Conference, biopharma trends
Alhemo: A Breakthrough in Hemophilia Treatment – FDA Approves Novo Nordisk’s Once-Daily Prophylactic Injection for Hemophilia A and B with Inhibitors
Alhemo, Novo Nordisk, Hemophilia A and B, Inhibitors, FDA Approval, Once-Daily Prophylactic Treatment, Concizumab